Modality
Gene Editing
MOA
C5i
Target
EZH2
Pathway
Proteasome
Pompe
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ Nov 2027
Phase 1Current
NCT05069648
2,232 pts·Pompe
2019-01→2027-11·Recruiting
2,232 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-201.6y awayInterim· Pompe
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2027-11-20 · 1.6y away
Pompe
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05069648 | Phase 1 | Pompe | Recruiting | 2232 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| Gelibrutinib | Sun Pharma | NDA/BLA | EZH2 | |
| RDY-3640 | Dr Reddy's | Preclinical | EZH2 | |
| QUO-6518 | Quotient Ther | Preclinical | CD38 |